NEW YORK (GenomeWeb) – Two commercially available sequencing platforms are capable of producing drug-resistance profiles for Mycobacterium tuberculosis, according to a new Genome Medicine study.

There has been a rise in recent years in the incidence of multidrug-resistant and extensively drug-resistant tuberculosis, but gauging the resistance profile of M. tuberculosis can be a slow and expensive process.